bispecifics

Regeneron, CytomX Ink Potentially $2B Bispecific Immunotherapy Deal
Regeneron, CytomX Ink Potentially $2B Bispecific Immunotherapy Deal
BioSpace
Regeneron
CytomX Therapeutics
bispecifics
cancer
Veloci-Bi
drug development
Flag link:
AstraZeneca bets $25M on preclinical bispecific against hot target, docking in Chinese Harbour to land global rights
AstraZeneca bets $25M on preclinical bispecific against hot target, docking in Chinese Harbour to land global rights
Fierce Biotech
AstraZeneca
Harbour BioMed
bispecifics
Flag link:
Aptevo Soars on Reports of Complete Remission in AML
Aptevo Soars on Reports of Complete Remission in AML
BioSpace
Aptevo
clinical trials
AML
APVO436
bispecifics
Flag link:
Novartis dumps 2nd bispecific from $2.6B Xencor pact, dealing further blow to hopes for blood cancer target
Novartis dumps 2nd bispecific from $2.6B Xencor pact, dealing further blow to hopes for blood cancer target
Fierce Biotech
Novartis
Xencor
bispecifics
blood cancers
Flag link:
Merck-partnered Janux hires CMO as its bispecifics near clinic
Merck-partnered Janux hires CMO as its bispecifics near clinic
Fierce Biotech
Janux Therapeutics
Merck
bispecifics
Flag link:
Roche eyes FDA filing after bispecific matches Eylea again
Roche eyes FDA filing after bispecific matches Eylea again
Fierce Biotech
Roche
bispecifics
Regeneron
Eylea
clinical trials
faricimab
wet age-related macular degeneration
Flag link:
ASH: J&J links subcut BCMA bispecific to 73% response rate, plots aggressive investment
ASH: J&J links subcut BCMA bispecific to 73% response rate, plots aggressive investment
Fierce Biotech
ASH2020
JNJ
bispecifics
Multiple Myeloma
teclistamab
Flag link:
Esmo 2020 – More encouraging signs for checkpoint bispecifics
Esmo 2020 – More encouraging signs for checkpoint bispecifics
EP Vantage
ESMO
bispecifics
Macrogenics
Akeso
mesothelioma
AK104
MGD019
Flag link: